Gilead Sciences, Inc. (GILD) Position Raised by OLD National Bancorp IN
OLD National Bancorp IN boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 16.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,092 shares of the biopharmaceutical company’s stock after purchasing an additional 4,561 shares during the period. OLD National Bancorp IN’s holdings in Gilead Sciences were worth $2,600,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Gilead Sciences in the second quarter valued at about $147,000. Hanson & Doremus Investment Management increased its holdings in Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 1,613 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its holdings in Gilead Sciences by 29.3% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 480 shares in the last quarter. Rowland & Co. Investment Counsel ADV purchased a new position in Gilead Sciences in the second quarter valued at about $153,000. Finally, Capstone Investment Advisors Netherlands B.V. purchased a new position in Gilead Sciences in the second quarter valued at about $172,000. Hedge funds and other institutional investors own 75.94% of the company’s stock.
A number of research analysts have issued reports on the stock. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a report on Thursday, August 31st. Wells Fargo & Co raised their price objective on shares of Gilead Sciences from $73.00 to $81.00 and gave the stock a “market perform” rating in a research note on Wednesday, September 6th. Oppenheimer began coverage on shares of Gilead Sciences in a research note on Thursday, October 5th. They set a “market perform” rating for the company. Credit Suisse Group reissued a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research note on Thursday, December 7th. Finally, Mizuho raised their price objective on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $85.03.
In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $74.64, for a total value of $1,119,600.00. Following the completion of the sale, the executive vice president now directly owns 70,988 shares of the company’s stock, valued at approximately $5,298,544.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders sold a total of 494,999 shares of company stock valued at $37,404,139 over the last ninety days. 1.30% of the stock is owned by corporate insiders.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $72.98 on Thursday. The company has a market cap of $95,310.00, a P/E ratio of 8.30, a price-to-earnings-growth ratio of -1.22 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. Gilead Sciences’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.75 EPS. equities analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.85%. Gilead Sciences’s payout ratio is currently 23.66%.
COPYRIGHT VIOLATION WARNING: This piece was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://theolympiareport.com/2017/12/28/gilead-sciences-inc-gild-position-raised-by-old-national-bancorp-in.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.